HONG KONG – Chinese pharmaceutical conglomerate Shanghai Fosun Pharmaceutical Group Co. Ltd. and Sellas Clinicals Holding AG have agreed to terminate an 8-month-old $530 million deal, which covered drug candidates for diabetes and cancer. Fosun said Sellas failed to settle a payment due. Sellas said Fosun declined to renegotiate terms of the deal, proposed because Sellas is seeking to do an initial public offering (IPO) and is realigning.